ABOUT NANOLOGICA

Nanologica is a Swedish nanotechnology company, world-leading in the development of nanoporous silica particles for purification by chromatography. Chromatography is a widely used technique for separating components in a mixture. We are active mainly in preparative chromatography, where we provide input goods to pharmaceutical manufacturers for purification of drugs during production.

Our mission is to increase the availability of cost-effective drugs, enabling more patients around the world access to vital treatments for diabetes and obesity. 

Nanologica’s products have been specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues,
and are produce according to a proprietary production method. Due to effective purification and a long lifetime for the products,
they can increase productivity and reduce costs for pharmaceutical manufacturers.

Nanologica operates in a global niche market that is growing as a result of an increased demand for drugs for treating diabetes and obesity.

The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

NLAB Saga®
A NEW GENERATION SILICA FOR PREPARATIVE CHROMATOGRAPHY

NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an
optimum choice for large scale purification of peptides.

News

Interim Report Q2 2024 Nanologica AB (publ)

FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 2,174 thousand (672) and for the half-year to SEK 7,211 thousand (1,026) Operating loss for the quarter amounted to SEK -9,832 thousand (-13,312) and for the half-year to SEK -25,163 thousand (-24,032) Loss before tax for the quarter amounted to SEK -11,126 thousand (-14,671)

Read more »

Nanologica Receives Order for NLAB Saga of approx SEK 2 Million

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China who has previously evaluated the product. The value amounts to approximately SEK 2 million. The customer is a pharmaceutical manufacturer that has evaluated NLAB Saga® on a small scale and has now placed an order for production.

Read more »

Listen to our team talk about Nlab Saga®

Play Video about Katarina Alenäs – SVP Chromatography

Interview with Katarina Alenäs,
SVP Chromatography

Play Video

Interview with Olga Krivosheeva, Ph.D.
Application Project Manager 

Play Video

Interview with Chunfang Zhou, Ph.D.
Sales Manager China

Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.

Presentation of Nanologica

For more videos presentations of the company and of interim reports, please refer to Investor Relations.

Company presentation made by CEO Andreas Bhagwani in June, 2023.

Investor Pitch Deck September 2023.

Please contact us at ir@nanologica.com for more information.